Prevent Cardiac Surgery Associated AKI Trial
Recruiting · NCT06620523 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
CoQ10 1200 mg orally with Glutathione 1000 mg orallyGroup B: Placebo CoQ10 orally and Placebo Glutathione orally
What this trial is about
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adult 18-70 years of age
- Undergoing elective CPB (Cardiopulmonary Bypass) surgery
- Baseline GFR (Glomerular Filtration Rate) ≥45 ml/min
Exclusion criteria
- GFR (Glomerular Filtration Rate) \<45 ml/min
- Solitary kidney
- Status post-kidney transplant
- Pregnant women
- Allergy to CoQ10
- Allergy to Glutathione
- Allergy to Cellulose
Where it is running
1 location listed across 1 US state.
- George Washington University Hospital - Washington D.C., District of Columbia, United States